- Home
- TALKW vs MREO Comparison
TALKW vs MREO Comparison
Compare TALKW & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TALKW
- MREO
- Stock Information
- Founded
- TALKW 2012
- MREO 2015
- Country
- TALKW United States
- MREO United Kingdom
- Employees
- TALKW 472
- MREO N/A
- Industry
- TALKW Medical/Nursing Services
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- TALKW Health Care
- MREO Health Care
- Exchange
- TALKW Nasdaq
- MREO Nasdaq
- Market Cap
- TALKW N/A
- MREO 482.5M
- IPO Year
- TALKW N/A
- MREO N/A
- Fundamental
- Price
- TALKW $0.11
- MREO $2.51
- Analyst Decision
- TALKW
- MREO Strong Buy
- Analyst Count
- TALKW 0
- MREO 6
- Target Price
- TALKW N/A
- MREO $7.83
- AVG Volume (30 Days)
- TALKW 64.2K
- MREO 1.5M
- Earning Date
- TALKW 02-20-2025
- MREO 03-26-2025
- Dividend Yield
- TALKW N/A
- MREO N/A
- EPS Growth
- TALKW N/A
- MREO N/A
- EPS
- TALKW N/A
- MREO N/A
- Revenue
- TALKW $181,291,000.00
- MREO $1,000,000.00
- Revenue This Year
- TALKW N/A
- MREO N/A
- Revenue Next Year
- TALKW N/A
- MREO N/A
- P/E Ratio
- TALKW N/A
- MREO N/A
- Revenue Growth
- TALKW 31.50
- MREO N/A
- 52 Week Low
- TALKW $0.20
- MREO $2.25
- 52 Week High
- TALKW $0.24
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- TALKW N/A
- MREO 38.01
- Support Level
- TALKW N/A
- MREO $2.25
- Resistance Level
- TALKW N/A
- MREO $2.65
- Average True Range (ATR)
- TALKW 0.00
- MREO 0.17
- MACD
- TALKW 0.00
- MREO 0.01
- Stochastic Oscillator
- TALKW 0.00
- MREO 38.81
About TALKW Talkspace Inc. Warrant
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue primarily stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).